Enoxaparin Metabolism in Reconstructive Surgery Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

June 30, 2016

Conditions
Venous ThromboembolismDeep Venous ThrombosisPulmonary EmbolusReconstructive Surgery
Interventions
DRUG

Enoxaparin

Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.

Trial Locations (1)

84132

University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT02411292 - Enoxaparin Metabolism in Reconstructive Surgery Patients | Biotech Hunter | Biotech Hunter